TTI-101 + atezolizumab + bevacizumab

TTI-101 + atezolizumab + bevacizumab is an experimental combination therapy comprising three agents with complementary mechanisms, currently investigated for advanced solid tumors such as hepatocellular carcinoma. **TTI-101** is an orally available, selective small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor crucial for cancer cell survival and immune evasion. **Atezolizumab** is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and enhancing antitumor immune responses. **Bevacizumab** is a recombinant humanized monoclonal IgG1 antibody binding vascular endothelial growth factor A (VEGF-A), thus inhibiting angiogenesis and restricting tumor blood supply. This combination targets oncogenic signaling, immune checkpoint suppression, and tumor angiogenesis, aiming to provide synergistic antitumor activity. Primary indications under investigation include unresectable or metastatic hepatocellular carcinoma and potentially other solid tumors[1][3][4][6][7][8].

Other names

bevacizumabatezolizumab